Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Intraspinal Steroid Therapy
Neurol 31:168-171, Bernat,J.L., 1981
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Intrathecal Baclofen for Severe Spinal Spasticity
NEJM 320:1517-1521, 1553-15551989., Penn,R.D.,et al, 1989
Intrathecal Baclofen for Long-Term Treatment of Spasticity:A Multi-Centre Study
JNNP 52:933-939, Ochs,G.,et al, 1989
Total Lymphoid Irradiation in Multiple Sclerosis:Blood Lymphocytes & Clinical Course
Ann Neurol 22:634-638, Cook,S.D.,et al, 1987
Continuous Intrathecal Baclofen for Severe Spasticity
Lancet 2:125-127, Penn,R.D.&Kroin,J.S., 1985
Dorsal Column Stimulation in Multiple Sclerosis:Effects on Bladder & Long Term Findings
BMJ 287:793-795, Hawkes,C.H.,et al, 1983
Stimulation of Dorsal Column in Multiple Sclerosis
BMJ 280:889-891, Hawkes,C.H.,et al, 1980
Dorsal Column Stimulation in Multiple Sclerosis
Editorial, BMJ 280:1287-12881980., , 1980
Failure of Chronic Dorsal Column Stimulation in Multiple Sclerosis
Ann Neurol 6:66-67, Rosen,J.A.,et al, 1979